Category: M&A / Deals
PharmaSignal — M&A / Deals
Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout
BioPharma Dive
The deal hands Neurocrine a controversial medicine, Vykat, that achieved $190 million in sales last year but faces persistent questions about its growth trajectory and safety, according to Wall Street
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal
BioSpace
While an acquisition is a good exit for Soleno Therapeutics, the company’s acceptance of Neurocrine Biosciences’ $53-per-share offer came as a surprise to Stifel analysts given the potential growth of
Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts
BioSpace
After a flurry of deals over the past week from Eli Lilly, Merck and Biogen, analysts predict more M A action from other big names, including Novartis, Amgen and AbbVie.
Merck KGaA acquires JSR chromatography business
Pharmaceutical Business Review
This follows the company’s signing of a definitive agreement in October 2025 to acquire the business.
Biocytogen and Sihuan partner to advance new therapeutics for weight loss
Pharmaceutical Business Review
Under the agreement, Biocytogen’s fully human antibody discovery platform will be combined with Sihuan Pharmaceutical’s capabilities in drug development, manufacturing, and commercialisation.
Merck KGaA acquires JSR chromatography business
Pharmaceutical Technology
Merck KGaA has completed its previously announced acquisition of the chromatography business of JSR Life Sciences.
Alzheimer’s biotech Korsana to go public via reverse merger
Pharmaphorum
By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer’s.
Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets
BioPharma Dive
In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help debt leverage ratios but also free up capacity to do other strategic deals.
Ambrosia adds a megaround for obesity drugs
BioPharma Dive
The $100 million Series B round will be used to bring the biotech s oral GLP-1 into early human testing.
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
BioSpace
Biogen, Eli Lilly, Merck and Novartis spent more than $20 billion to absorb biotechs with promising or approved drugs; the rare disease space notched approvals for therapies from Denali Therapeutics,
Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B
BioSpace
While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule approach.
Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout
Pharmaceutical Technology
Biogen’s acquisition of Apellis Pharmaceuticals will add Syfovre and Empaveli to the latter company’s portfolio of medicines.
Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa
Pharmaceutical Technology
Whether the deal reaches its full value hinges on US regulatory milestones for Centessa’s lead candidate, cleminorexton.
Symeres and Ambagon collaborate for colorectal cancer molecules
Pharmaceutical Business Review
The partnership aims to explore a new class of small molecules, called molecular glues, which enable or stabilise interactions between proteins.
Lilly beefs up neuroscience pipeline with $6.3B Centessa buyout
BioPharma Dive
The deal secures two sleep disorder drugs that would fill a hole in the company s portfolio and intensify a competition with Takeda and Eisai.
Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy
BioSpace
In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in
Biogen, with $5.6B Apellis buy, builds out immunology offerings
BioPharma Dive
Chief Financial Officer Robin Kramer explained how the deal not only provides two marketed products, but a team with nephrology expertise that will be valuable as Biogen prepares to launch felzartamab
Biogen swoops on Apellis with $5.6bn offer
Pharmaphorum
In today’s second sizeable M A deal, Biogen has agreed to buy Apellis for around $5.6 billion, building on its aspirations in nephrology.
Eli Lilly makes $7.8bn takeover play for Centessa
Pharmaphorum
Sleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech.
Merck strikes deal with antibody discovery startup
BioPharma Dive
In an R D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed antibodies for multiple targets.